Scientists at Stanford Medicine have identified a naturally occurring molecule called BRP that mimics some weight loss effects of semaglutide, the active ingredient in Ozempic. In animal studies, BRP reduced appetite and body weight while avoiding side effects such as nausea, constipation, and muscle loss. This breakthrough highlights a potential "natural Ozempic" alternative focused on brain-specific pathways.
The Obesity Challenge and Need for Targeted Therapies
Obesity affects millions worldwide, driving risks for diabetes, heart disease, and metabolic disorders. Drugs like Ozempic (semaglutide), a GLP-1 receptor agonist, have transformed treatment by curbing appetite and promoting weight loss. However, their broad effects—stemming from receptors in the brain, gut, pancreas, and other tissues—often lead to gastrointestinal issues and other side effects.
Enter BRP (BRINP2-related peptide), derived from the prohormone BRINP2. Unlike semaglutide, which slows digestion and lowers blood sugar alongside appetite suppression, BRP acts primarily in the hypothalamus, the brain region regulating hunger and metabolism. "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," explained Katrin Svensson, PhD, assistant professor of pathology at Stanford and senior author of the study. "That's why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
How Artificial Intelligence Powered the BRP Discovery
The path to BRP relied on cutting-edge artificial intelligence. Traditional lab methods struggle to identify bioactive peptides from prohormones—precursor molecules cleaved into smaller, hormone-like fragments. Prohormones can be split in countless ways, making it hard to pinpoint rare signaling peptides amid inactive debris from protein breakdown.
Researchers zeroed in on prohormone convertase 1/3, an enzyme linked to obesity that cleaves proteins at precise sites. A famous output is glucagon-like peptide 1 (GLP-1), which semaglutide mimics to regulate appetite and blood sugar.
To accelerate discovery, the team created Peptide Predictor, an AI algorithm scanning all 20,000 human protein-coding genes for prohormone cleavage sites. It prioritized secreted proteins with multiple cleavage points, yielding 373 prohormone candidates and predicting 2,683 peptides. "The algorithm was absolutely key to our findings," Svensson noted.
From these, 100 peptides—including GLP-1—were synthesized and tested on lab-grown brain cells. GLP-1 boosted neuron activity as expected, but BRP, a tiny 12-amino-acid peptide, delivered a tenfold stronger response.
Key Steps in the AI-Driven Screening Process
- Gene Scanning: Analyzed 20,000 protein-coding genes for cleavage patterns.
- Filtering: Focused on secreted proteins, reducing to 373 prohormones.
- Prediction: Generated 2,683 peptide candidates.
- Testing: Selected 100 for neuron activity assays, identifying BRP's superior effect.
BRP's Mechanism: A Precise Brain-Targeted Approach
BRP activates distinct neuron groups via a pathway related but separate from GLP-1/semaglutide. This specificity promises fewer off-target effects. Ongoing research aims to map BRP's exact receptors and extend its half-life for practical dosing.
The study, published in Nature, was led by senior research scientist Laetitia Coassolo, PhD. Svensson has co-founded Merrifield Therapeutics to advance human trials.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Animal Studies: Impressive Weight Loss Without Side Effects
BRP shone in rigorous animal models. In lean mice and minipigs (better mimicking human metabolism than rodents), a single pre-meal injection cut food intake by up to 50% within an hour.
In obese mice, 14 days of daily injections caused 3 grams of average weight loss—mostly fat—while controls gained 3 grams. Treated mice also improved glucose and insulin tolerance.
Crucially, no changes occurred in movement, water intake, anxiety-like behavior, or digestion. Analyses confirmed BRP's unique brain and metabolic pathways, distinct from GLP-1 drugs.
BRP vs. Semaglutide: A Side-by-Side Comparison
| Aspect | BRP | Semaglutide (Ozempic) |
|---|---|---|
| Target | Hypothalamus-specific | Brain, gut, pancreas, widespread | Weight Loss (Obese Mice, 14 days) | -3g (fat-focused) | Appetite reduction + GI effects | Side Effects Observed | None (nausea, digestion, etc.) | Nausea, constipation, muscle loss possible |
| Food Intake Reduction | Up to 50% (single dose) | Significant, multi-pathway |
Safety Profile and Implications for Patients
BRP's clean animal profile—no nausea, constipation, or muscle loss—addresses key GLP-1 limitations. While human trials are pending, this targeted action could benefit patients intolerant to Ozempic's GI issues.
Patients considering peptide therapies should consult physicians. Discuss family history, comorbidities, and monitor via apps like Shotlee for symptoms or schedules during trials. BRP isn't available yet; stick to approved options like semaglutide under medical supervision.
"The lack of effective drugs to treat obesity in humans has been a problem for decades," Svensson said. "Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
Collaborations, Funding, and Next Steps
The work spanned Stanford, UC Berkeley, University of Minnesota, and University of British Columbia. Funding included NIH grants (R01DK125260, P30DK116074, K99AR081618, GM113854), Stanford programs, American Heart Association, Carlsberg Foundation, and Wu Tsai Human Performance Alliance.
Svensson and Coassolo hold BRP-related patents for metabolic disorders; Svensson co-founded Merrifield Therapeutics for clinical advancement.
Key Takeaways: What This Means for Metabolic Health
- Precision Targeting: BRP's hypothalamus focus may minimize side effects vs. broad GLP-1 agonists.
- AI Innovation: Peptide Predictor unlocks vast peptide potential for drug discovery.
- Promising Data: Up to 50% appetite reduction, 3g fat loss in 14 days (mice), no adverse behaviors.
- Future Watch: Human trials via Merrifield Therapeutics could yield a "natural Ozempic."
- Patient Action: Explore GLP-1s now; track progress and stay informed on BRP developments.
Conclusion: A Step Toward Safer Weight Management
Stanford's BRP discovery offers hope for obesity treatment—a potent, side-effect-free peptide rivaling Ozempic's efficacy through smarter targeting. As human trials loom, it underscores AI's role in metabolic health. Patients: Partner with doctors for personalized plans, blending lifestyle, approved meds, and emerging therapies like BRP.
